Circular RNA circRNA_0067934 promotes glioma development by modulating the microRNA miR-7/ Wnt/β-catenin axis

Pei, Yunlong; Zhang, Hongying; Lu, Kongye; Tang, Xiaojia; Li, Jialing; Zhang, Enpeng; Zhang, J.; Huang, Yujia; Yang, Zhijie; Lu, Zhenggang; Li, Yuping; Zhang, Hengzhu

doi:10.1080/21655979.2022.2033382

Cited by 14 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The microarray analysis showed that miR-7 was upregulated at the highest degree in cells after curcumol treatment. miR-7 has been recognized as a tumor inhibitor that suppresses tumor proliferation and metastasis [, 33–36 , 37 ]. In this work, miR-7 inhibition was introduced in cells after curcumol treatment.…”

Section: Discussionmentioning

confidence: 99%

Curcumol enhances cisplatin sensitivity of gastric cancer: involvement of microRNA-7 and the nuclear factor-kappa B/snail family transcriptional repressor 1 axis

et al. 2022

Bioengineered

View full text Add to dashboard Cite

Cisplatin is a primary chemotherapeutic drug for gastric cancer (GC) patients, but the drug resistance remains the leading cause of treatment failure and high mortality. Curcumol is a bioactive sesquiterpenoid that has reportedly been linked to cisplatin sensitivity in GC. This study focuses on the exact functions of curcumol in the cisplatin sensitivity of GC cells and the molecules of action. The curcumol treatment reduced the viability and migration and enhanced cisplatin sensitivity of GC cells in a dose-dependent manner. Microarray analysis suggested that microRNA-7 ( miR-7 ) was the most upregulated miRNA in GC cells after curcumol treatment. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis showed that the curcumol-affected genes, including the target genes of miR-7, were enriched in the nuclear factor-kappa B (NF-κB) pathway, whose activity was suppressed after curcumol treatment. miR-7 was found to target and suppress RELA proto-oncogene ( RELA , also known as p65), a NF-κB subunit. Downregulation of miR-7 blocked the sensitizing effects of curcumol on cells to cisplatin and led to increased expression of NF-κB p65 and snail family transcriptional repressor 1 (SNAIL). Further downregulation of RELA enhanced, whereas upregulation of SNAIL suppressed the sensitivity again. In summary, this study suggests that curcumol sensitizes GC cells to cisplatin via miR-7 and the suppression of the NF-κB/SNAIL axis. The findings may offer new thoughts that curcumol in combination with cisplatin might be a useful strategy for GC management.

show abstract

Section: Discussionmentioning

confidence: 99%

Curcumol enhances cisplatin sensitivity of gastric cancer: involvement of microRNA-7 and the nuclear factor-kappa B/snail family transcriptional repressor 1 axis

et al. 2022

Bioengineered

View full text Add to dashboard Cite

show abstract

“…After the slides were washed, the arrays were scanned with an Agilent Scanner G2505C. The target miRNAs were predicted based on Cancer-Specific CircRNA Database, while targeted mRNAs were predicted based on TargetScan, miRDB, and miRTarBase [ 17 ].…”

Section: Methodsmentioning

confidence: 99%

“…For example, circDIDO1ʹs regulation of hepatic stellate cells requires the participation of mir-141-3p [ 16 ]. Similarly, circRNA_0067934 promotes glioma development with the help of microRNA miR-7 [ 17 ], and hsa_circ_0008896 accelerates atherosclerosis in a process that requires the participation of hsa-miR-633 [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Hsa_circ_0000081 promotes the function of gastric cancer through sponging hsa-miR-423-5p to influence 3-phosphoinositide-dependent kinase 1 expression

Jiang

Cao

et al. 2022

Bioengineered

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common malignancies in the world, and effective therapeutic targets need to be identified for this type of cancer. In this study, circular RNA (circRNA) microarray analysis was utilized to screen differentially expressed circRNA in GC. Using quantitative reverse transcription polymerase chain reaction (qRT-PCR), hsa_circ_0000081 (circRNA-0000081) expression was found to be up-regulated in tissues and cells and was negative correlated with patients’ survival time. RNase R and Actinomycin D assays indicated that circRNA-0000081 was significantly more resistant to R enzyme and had a longer half-life than linear RNA. Moreover, the knockdown or overexpression of circRNA-000081 could influence the proliferation, migration, and invasion potential of GC. Finally, dual luciferase reporter, RNA immunoprecipitation, qRT-PCR, and western blotting assays were used to verify the targeting relationship between circRNA-000081 and miRNA-423-5p or miRNA-423-5p and 3-phosphoinositide-dependent kinase 1 (PDPK1). In conclusion, circRNA-0000081 promotes the function of GC through sponging hsa-miR-423-5p to influence PDPK1 expression, which has a promising therapeutic potential for treating patients with GC.

show abstract

“…82 Circ_0001730, cZNF292, circRNA_0067934, and circ_0000177 could modulate the miRNA/Wnt/β-catenin axis and control glioma cell progression. [83][84][85][86] F I G U R E 2 CircRNA and signaling in glioma. Examples of circRNAs regulating signaling to modulate tumorigenesis in gliomas.…”

Section: Circrna and G LI Omamentioning

confidence: 99%

The regulatory role and clinical application prospects of circRNA in the occurrence and development of CNS tumors

Zhang,

Wang

et al. 2023

CNS Neurosci Ther

View full text Add to dashboard Cite

BackgroundCentral nervous system (CNS) tumors originate from the spinal cord or brain. The study showed that even with aggressive treatment, malignant CNS tumors have high mortality rates. However, CNS tumor risk factors and molecular mechanisms have not been verified. Due to the reasons mentioned above, diagnosis and treatment of CNS tumors in clinical practice are currently fraught with difficulties. Circular RNAs (circRNAs), single‐stranded ncRNAs with covalently closed continuous structures, are essential to CNS tumor development. Growing evidence has proved the numeral critical biological functions of circRNAs for disease progression: sponging to miRNAs, regulating gene transcription and splicing, interacting with proteins, encoding proteins/peptides, and expressing in exosomes.AimsThis review aims to summarize current progress regarding the molecular mechanism of circRNA in CNS tumors and to explore the possibilities of clinical application based on circRNA in CNS tumors.MethodsWe have summarized studies of circRNA in CNS tumors in Pubmed.ResultsThis review summarized their connection with CNS tumors and their functions, biogenesis, and biological properties. Furthermore, we introduced current advances in clinical RNA‐related technologies. Then we discussed the diagnostic and therapeutic potential (especially for immunotherapy, chemotherapy, and radiotherapy) of circRNA in CNS tumors in the context of the recent advanced research and application of RNA in clinics.ConclusionsCircRNA are increasingly proven to participate in decveloping CNS tumors. An in‐depth study of the causal mechanisms of circRNAs in CNS tomor progression will ultimately advance their implementation in the clinic and developing new strategies for preventing and treating CNS tumors.

show abstract

Circular RNA circRNA_0067934 promotes glioma development by modulating the microRNA miR-7/ Wnt/β-catenin axis

Cited by 14 publications

References 38 publications

Curcumol enhances cisplatin sensitivity of gastric cancer: involvement of microRNA-7 and the nuclear factor-kappa B/snail family transcriptional repressor 1 axis

Curcumol enhances cisplatin sensitivity of gastric cancer: involvement of microRNA-7 and the nuclear factor-kappa B/snail family transcriptional repressor 1 axis

Hsa_circ_0000081 promotes the function of gastric cancer through sponging hsa-miR-423-5p to influence 3-phosphoinositide-dependent kinase 1 expression

The regulatory role and clinical application prospects of circRNA in the occurrence and development of CNS tumors

Contact Info

Product

Resources

About